Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
|Articles|August 18, 2015
Hope Rugo on Managing Effects From Ovarian Suppression in Patients With Breast Cancer
Author(s)Hope S. Rugo
Hope S. Rugo discusses managing effects from ovarian suppression treatment for breast cancer.
Advertisement
Hope S. Rugo, from the University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, discusses managing effects from ovarian suppression treatment for breast cancer.
Advertisement
Related to this article
A woman treated for DCIS breast cancer with a double mastectomy shares why her smoother recovery left her with survivor guilt and feeling like an impostor.
Dr. Sara Hurvitz explains why giving Enhertu before surgery didn't change care for HER2-low, HR-positive early breast cancer, and what patients should know.
Brad Dugai and Russ Reed discuss symptom relief, skin-related side effects and challenges accessing Rasonque, a treatment for pancreatic cancer.
A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.
A breast cancer survivor shares how cancer turned gratitude into an everyday practice and why it's OK when the holidays bring both joy and grief this year.
Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.
Advertisement
Advertisement
Trending on CURE
1
Why a Patient With Pancreatic Cancer Moved From Chemotherapy to Rasonque
2
Rasonque for Pancreatic Cancer: Patients Discuss Benefits, Risks and Access
3
5 Lung Cancer Immunotherapy Side Effects and How to Manage Them
4
FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
5